![Gerald Hogue](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gerald Hogue is the founder of OpTx Corp.
(founded in 1993) and Viviphi Ltd. (founded in 2015, title: Chairman, President & Chief Executive Officer).
Mr. Hogue is currently a Director at POINT Biopharma, Inc. (since 2020).
Formerly, Independent Director at POINT Biopharma Global, Inc. (2021-2023).
| Unternehmen | Position | Beginn |
|---|---|---|
POINT Biopharma, Inc. (United States)
 POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Develops next-generation radioligand therapies for the treatment of cancer | Direktor/Vorstandsmitglied | 01.12.2020 |
| Unternehmen | Position | Ende |
|---|---|---|
| POIT BIOP | Direktor/Vorstandsmitglied | 27.12.2023 |
Viviphi Ltd.
 Viviphi Ltd. Packaged SoftwareTechnology Services Provides artificial intelligence informatics software platform for cancer care | Vorstandsvorsitzender | 01.12.2023 |
OpTx Corp.
 OpTx Corp. Packaged SoftwareTechnology Services Provides oncology-specific software and services providers | Gründer | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 4 |
|---|---|
OpTx Corp.
OpTx Corp. Packaged SoftwareTechnology Services Provides oncology-specific software and services providers | Technology Services |
Viviphi Ltd.
Viviphi Ltd. Packaged SoftwareTechnology Services Provides artificial intelligence informatics software platform for cancer care | Technology Services |
POINT Biopharma Global, Inc.
 POINT Biopharma Global, Inc. BiotechnologyHealth Technology Develops radioligand therapies for the treatment of cancer | Health Technology |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Develops next-generation radioligand therapies for the treatment of cancer | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
